ISSN 2756-3340
African Journal of Infectious Diseases Research | Vol. 13, No. 11, November 2026 | pp. 001–014
Article Type: Full Length Research Paper
Title: Preclinical safety assessment of the Ad26.CoV2-S vaccine in male Wistar rats: biochemical and histopathological study following phytotherapeutic preconditioning
Names of Authors: Dimitry Moudiongui Mboungou Malanda¹˒²˒³, Bredin Roch Bissala Nkounkou¹, Archange Michel Emmanuel Mboungou Malonga¹, Paola Candyse Tsimba Lemba¹, Elamette Gnyassiba Balebou¹, Syrlie Marina Osseke¹, Landry Martial Miguel¹
¹ Faculty of Health Sciences, Marien Ngouabi University, Brazzaville, Republic of the Congo;
² Department of Anatomy and Cytopathology, Brazzaville University Hospital, Brazzaville, Republic of the Congo;
³ Research Unit in Virology and Molecular Biology at the FSSA, Brazzaville, Republic of the Congo.
Abstract:
Introduction: COVID-19 led to the development of the Ad26.CoV2-S vaccine, a recombinant adenoviral vector expressing the SARS-CoV-2 spike protein. Despite its demonstrated clinical efficacy, its preclinical safety profile requires further evaluation.
Objective: This study aims to analyze the biochemical and histopathological effects of the vaccine in Wistar rats, using a plant extract preconditioning model.
Materials and Methods: Twenty male rats were divided into five groups: an unimmunized control, groups pretreated with Immu-C®, G. kola, or Z. officinale followed by immunization, and a vaccinated control. The animals received the treatments for seven days and were then immunized with Ad26.CoV2-S. The parameters studied included transaminases (ALT, AST), creatinine, and histopathological lesions of the liver, lungs, and spleen.
Results: The results show irregular variations in transaminases, a generally stable creatinine level, and predominantly pulmonary lesions (alveolar congestion and hemorrhage), with limited hepatic and splenic involvement. Two deaths were observed in the vaccinated group after the second immunization.
Conclusion: Immunization with Ad26.CoV2-S is associated with moderate biological changes dominated by inflammatory pulmonary lesions, with relative preservation of hepatic and renal function.
Keywords: Ad26.CoV2-S, Phytotherapeutic preconditioning, Biochemistry, Histopathology, Wistar rat.
Citation: Malanda D M M, Nkounkou B R B, Malonga A M E M, Lemba P C T, Balebou E G, Osseke S M and Miguel L M (2026). Preclinical safety assessment of the Ad26.CoV2-S vaccine in male Wistar rats: biochemical and histopathological study following phytotherapeutic preconditioning. African Journal of Infectious Diseases Research, 13(11): 001–014.
Manuscript Timeline: Received: June 29, 2026; Revised: October 30, 2026; Accepted: November 01, 2026; Published: November 2026